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Abstract
Classical non-homologous end joining 1 (cNHEJ) and homologous recombination 2 (HR) compete 
for the repair of double stranded breaks of DNA during the cell cycle. HR is inhibited in G1 phase 
of the cell cycle, but both pathways are active in S and G2 phases. Why cNHEJ does not always 
outcompete HR in S and G2 phases has been unclear. Here we show that CYREN is a cell cycle 
specific inhibitor of cNHEJ. CYREN suppression allows cNHEJ at telomeres and 
intrachromosomal breaks during S and G2 phases, while cells lacking CYREN accumulate 
chromosomal aberrations upon damage induction, specifically outside G1 phase. CYREN acts by 
binding to the Ku70/80 heterodimer and preferentially inhibits cNHEJ at breaks with overhangs by 
protecting them. We therefore propose that CYREN is a direct cell cycle inhibitor of cNHEJ, 
thereby promoting error free repair by HR in cell cycle phases where sister chromatids are present.
The cNHEJ machinery recognizes breaks, indiscriminately joins them and is therefore 
potentially genotoxic 1. HR relies on the generation of 3’ overhangs, which invade 
homologous sister chromatids to promote error free break repair 2. Choice between HR and 
cNHEJ depends primarily on the cell cycle stage and the nature of the break. During G1 
phase HR is inactivated, and cNHEJ is dominant, but during S and G2 phases, when sister 
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chromatids are available, cNHEJ and HR compete 3. While the inhibition of HR during G1 
is well understood, it is unclear why the abundant cNHEJ machinery does not dominate in S 
and G2, pointing at an active cNHEJ suppressor mechanism during and after replication. 
Similarly, fusions of deprotected telomeres, which occur through cNHEJ exclusively, are 
restricted to G1 4,5. End resection, which promotes HR, is inhibited by RIF1 and 53BP1 
during G1, thereby restricting HR activity to S/G2 6–8. During S/G2, when both pathways 
are active 9, end-resection by CtIP is activated, which can inhibit cNHEJ 10. However, it is 
unclear how cNHEJ is restricted in S and G2 to allow resection and commencement of HR 
for error-free repair of lesions. CYREN (Cell cYcle REgulator of NHEJ) was originally 
identified as potential modulator of retroviral infection 11. Later, the alternatively spliced 
isoform CYREN-2 was found as short open reading frame translated polypeptide and to 
interact with the Ku70/80 heterodimer 12. We therefore tested the role of CYREN in cNHEJ 
and found it to be a cell cycle regulator of cNHEJ.
TRF2 is the main telomere protection factor by stabilizing the t-loop and inhibiting the ATM 
kinase and RNF168 13–15. Depletion of TRF2 leads to ATM activation 16 and subsequent 
activation of cNHEJ, leading to chromosome end-to-end fusions 17, while HR and 
alternative NHEJ (altNHEJ) remain inhibited by shelterin and Ku70/80 18–20. Chromosome 
fusions prior to replication occur between the single chromatids of two chromosomes, 
leading to chromosome-type fusions after replication, where both sister chromatids are 
fused. When fusions occur after replication, only one sister chromatid is engaged in the 
fusion, leading to chromatid-type fusions (Figure 1a). Chromosomes fused as a result of 
TRF2 loss display as chromosome-type fusions during metaphase, demonstrating that the 
fusion process is restricted to G1 of the cell cycle and suppressed during S and G2 4,5,21,22. 
The emergence of chromatid type fusion signifies a derepression of cNHEJ in S and G2 
(Figure 1a), representing a powerful system to investigate DSB repair pathway choice. To 
study the role of CYREN in cNHEJ, we generated HT1080 6TG cells with three stably 
integrated inducible shRNAs targeting CYREN (shCYREN#A,B,C), which were induced 
after TRF2 depletion followed by metaphase analysis (Extended data Figure 1a-c, Extended 
data Figure 10). Depletion of TRF2 alone led to chromosome type G1 fusions, while 
chromatid-type fusions were rare (Figure 1b-c, Extended data Figure 1d-e). Overall 
chromosome-type telomere fusion frequency was unaltered by CYREN depletion (Figure 
1c, Extended data Figure 1d-e, g), indicating that CYREN is not part of the cNHEJ 
machinery. Instead, depletion of CYREN and TRF2 led to a five-fold increase in chromatid-
type fusions (Figure 1b-c, Extended data Figure 1d-e, g), suggesting that CYREN could 
suppress cNHEJ in S and G2 at deprotected telomeres. Sister telomere associations were not 
increased (Extended data Figure 1f-g) and cell cycle dynamics were not perturbed by 
shRNA treatment (Figure 1d). Untransformed IMR90+E6E7 fibroblasts reacted comparably 
(Extended data Figure 2a-d). CYREN depletion did not lead to chromatid-type fusions at 
intact telomeres, indicating that CYREN itself does not play a role in end protection (Figure 
1b-c, Extended data Figure 2d-e).
Chromosome-Oriented FISH on CYREN and TRF2 co-depleted cells found no bias in the 
type of chromatid involved in the chromatid-type fusions, ruling out that the observed 
fusions are a result of unprocessed leading strand overhangs 23,24 (Extended data Figure 3a-
b). To determine whether the fusions were the result of cNHEJ or altNHEJ activation, we 
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depleted ATM, Ligase 4, DNA-PKcs and Ligase 3 in TRF2-suppressed CYREN wild type 
and knockout cells (Extended data Figure 3c-d). Only ATM, Ligase 4 or DNA-PKcs 
depletion suppressed both chromosome- and chromatid-type fusions, indicating that 
CYREN regulates cNHEJ, not altNHEJ (Figure 1e). ATM, DNA-PKcs or PARP inhibitors 
25–27 yielded comparable results, while inhibition of RAD51 28 had no effect, excluding 
that CYREN controls HR (Extended data Figure 3e-f). ATM and DNA-PKcs inhibition for 
48 hours suppressed both chromosome- and chromatid-type fusions, but only the chromatid-
type fusions were suppressed when inhibition occurred during S and G2 phases, while 
inhibition during G2 had an intermediate effect (Figure 1f), confirming that CYREN inhibits 
cNHEJ in S and G2 phase at deprotected telomeres.
To demonstrate that CYREN is a genome-wide regulator of DSB repair pathway choice, we 
first tested the effects of CYREN deletion on the repair of irradiation-induced 
intrachromosomal breaks. While three synchronized CYRENwt and CYRENKO clones 
(Extended data Figure 10) accumulated rearrangements or bridges after irradiation in G1, 
cells lacking CYREN amassed significantly more abnormalities when irradiated during and 
after replication (Figure 2 a-b, Extended data Figure 4 a-b), pointing at a role of CYREN at 
intrachromosomal breaks in S and G2. We then designed an in vivo fluorescence-based 
reporter system that allows the quantitative comparison of cNHEJ and alt-NHEJ versus HR 
in the same cells through the repair of two inverted ISce1 cuts. Repair through NHEJ or HR 
leads to GFP or mCherry expression, respectively, while transfection efficiency was 
controlled using BFP expression from the repair donor cassette (Figure 2c, Extended data 
Figure 4c-d, Extended data Figure 10). We confirmed that all isolated reporter clones 
(Extended data Figure 4e) followed the same cell cycle kinetics (Extended data Figure 4e) 
and analysed the outcome of repair by flow cytometry. The CYREN knockout clones 
utilized NHEJ significantly more frequently than the wild type clones, while HR was 
significantly reduced in the same cells (Figure 2d). CYREN depletion did not lead to the 
formation of radial chromosomes, or to an increase in radials in cells lacking Brca1, or a 
decrease in survival (Extended data Figure 5a-c), arguing against the role of CYREN in 
replication-induced DSB repair pathway, where HR is dominant.
As a result of alternative splicing of C7orf49, three isoforms of CYREN are generated 
(Figure 3a), of which isoforms 1 and 2 were found to bind to Ku70/80 12. We expressed the 
Flag-tagged isoforms, depleted TRF2 and suppressed endogenous CYREN by targeting the 
3’ UTR of C7orf49 (Extended data Figure 6a-b). 3’ UTR siCYREN increased chromatid-
type fusions in control cells or cells expressing CYREN-3, but CYREN-1 or CYREN-2 
rescued the phenotype (Figure 3b), indicating that they inhibit cNHEJ.
To verify the endogenous expression levels of the isoforms we inserted a 3xFLAG tag at the 
N-terminus of CYREN-1 and 2 and the C-terminus of CYREN 1 and 3 (Extended data 
Figure 6c-h, Extended data Figure 10). CYREN-1 was six to seven times more abundant 
than CYREN-2 (Extended data Figure 6e), CYREN-3 expression was not detectable 
(Extended data Figure 6h) and the siCYREN approach indeed targeted endogenous CYREN 
(Extended data Figure 6i). We therefore focused on CYREN-1.
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To identify the CYREN-1-Ku interaction domain, we incubated a CYREN-1 peptide array 
with recombinant Ku70/80 (Extended data Figure 7a). Ku70/80 bound to several peptides on 
the N-terminus of CYREN-1, a region that is lacking in isoform 3. Alanine mutagenesis, 
followed by co-immunoprecipitation of Ku70/80 with mutated CYREN-1, identified R11, 
P14 and W16 as the precise interaction domain (Figure 3c, Extended data Figure 7b). These 
highly conserved residues (Extended data Figure 7c) are part of the Ku-binding motif 
(KBM), previously also described in APLF, CYREN and WRN and shown to interact with a 
hydrophobic pocket in the vWA domain of Ku80 29. We incubated a synthetic UV-
crosslinkable BPA-BIO-CYREN peptide with cell lysate, followed by UV crosslinking and 
biotin pulldown, and confirmed the direct CYREN KBM-Ku80 interaction (Extended data 
Figure 7d).
Co-depletion of CYREN and TRF2 again led to chromatid-type fusions, which were 
suppressed by exogenous expression of wild type CYREN-1 as well as CYREN-1R11A 
(Extended data Figure 7e, Figure 3d). In contrast, expression of the CYREN-1P14A and 
CYREN-1W16A mutants, as well as the triple mutant CYREN-1RPW-AAA, failed to rescue 
the chromatid-type fusions (Figure 3d), indicating that the CYREN mediated inhibition of 
cNHEJ critically depends on the interaction of CYREN with Ku.
Because CYREN activity is strictly restricted to S and G2, we examined the cell cycle 
regulation of CYREN. CYREN-1 and CYREN-2 mRNA levels, endogenous C-terminally 
tagged CYREN-1 or endogenous N-terminally tagged CYREN-1 and CYREN-2 proteins 
were not cell cycle regulated (Figure 3e-f, Extended data Figure 7f). In contrast, the 
interaction of CYREN with the Ku heterodimer was restricted to S and G2 of the cell cycle 
(Figure 3g-h), explaining the cell cycle dependency of CYREN based c-NHEJ inhibition.
To understand whether CYREN has a preference for break sites with pre-existing overhangs, 
we generated breaks that either bear blunt ends or 5’ or 3’ overhangs of different lengths at 
an m-Clover-LaminA reporter (Figure 4a, Extended data Figure 10). We found that although 
CYREN depletion did not affect the repair of blunt ends, HR was reduced at breaks with 
overhangs (Figure 4b, Extended data Figure 8a). The reduction reached up to 40% at breaks 
with long 3’ overhangs, suggesting that CYREN preferentially regulates cNHEJ at breaks 
with overhangs, consistent with the strong cNHEJ inhibition observed at telomeres. To 
analyse a potential role for CYREN in overhang processing during cNHEJ, we used the 
same reporter system without providing a HR donor. Deep sequencing and analysing the 
deletions at the repair junctions revealed no increased deletion frequencies at blunt ends, but 
the lack of CYREN led to increased deletions of the 5’ and 3’ overhangs, indicating that 
CYREN prevents the processing of overhangs (Figure 4c, Extended data Figure 8b). This 
phenotype was rescued by CYRENwt expression, but not by CYREN mutant that fails to 
interact with Ku70/80 (Extended data Figure 8c-d). The data suggest that CYREN protects 
the single stranded overhangs at break sites, thereby creating a local environment that 
favours HR, while preventing cNHEJ dependent repair.
CYREN had previously been described as stimulator of end joining in vitro 12. However, 
when we compared in vitro NHEJ activities of CYREN knockout with wild type clones, we 
did not observe differences (Extended data Figure 9a). Similarly, purified wild type CYREN 
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or CYREN incapable of binding to Ku did not stimulate end joining activity (Extended data 
Figure 9b), leading us to the conclusion that the small differences reported previously were 
likely the consequences of oversaturating the reaction with recombinant protein.
CYREN represents a novel class of pathway choice regulators that is not a functional part of 
the cNHEJ or HR machineries per se. Possibly the CYREN-Ku interaction diminishes 
binding of Ku to break sites with overhangs. Similarly, CYREN could compete for Ku 
binding with other KBM containing factors in vivo, thereby obstructing initiation of the 
NHEJ process and giving the resection machinery an advantage, consistent with the 
observation that HR is favoured when rapid end joining by NHEJ is inhibited 30. While 
inhibition of HR at replication-induced breaks eventually leads to repair by cNHEJ even in S 
and G2, cNHEJ at telomeres remains inhibited, possibly because the overhangs of two 
deprotected telomeres are not cohesive and fusion depends on overhang processing, which 
does not apply to the cohesive overhangs induced by nickase. CYREN could therefore 
suppress the fusion of distal breaks bearing overhangs and prevent translocations in S and 
G2. Finally, understanding CYREN will permit an in-depth analysis of the cell cycle 
regulated Ku-CYREN interaction and the potential effects on toxicity of error prone repair, 
whether unleashing cNHEJ in cell cycle phases other than G1 will predispose organisms to 
cancer and whether deregulation of cNHEJ in S and G2 sensitizes cancer cells to genotoxic 
drugs.
Methods
Cell culture
HT1080, HT1080 6TG (ATCC) and their derivatives cells were grown in Glutamax-DMEM 
supplemented with 0.1 mM nonessential amino acids and 10% bovine growth serum. Human 
IMR-90 primary lung fibroblasts transformed with E6E7 1 were grown in Glutamax-DMEM 
(Gibco) supplemented with 0.1 mM nonessential amino acids and 15% fetal bovine serum. 
All cells were grown at 7.5% CO2 and 3% O2. All cell lines were purchased from ATCC or 
have been commercially authenticated and tested free of mycoplasma. When indicated, cells 
were treated with the following inhibitors: ATMi (KU-55933, Tocris, 10µM), DNA-PKcsi 
(NU-7441, Tocris, 1µM), PARPi (Olaparib, Selleck Chemical, 10µM), RAD51i (RI-1, 
Selleck Chemical, 20µM).
Plasmids, transfections and infections
TRF2 shRNA in pLKO.1 was obtained from Open biosystems. The non-coding control 
shRNA in pLKO.1 was obtained from David Sabatini via Addgene (Plasmid 1864, 2). 
Inducible Luciferase control and CYREN shRNAs in a pRSITUR plasmid were obtained 
from Cellecta, target sequences are listed bellow. CYREN-1-Flag, CYREN-2-Flag and 
CYREN-3-Flag were cloned in pCDNA3 plasmid. Inducible CYREN-1-3xFlag and its 
mutant derivatives were cloned in pLIX lentiviral inducible expression vector, obtained from 
David Root via Addgene (Plasmid 41395). Small guide RNAs targeting CYREN (target 
sequences detailed bellow) were cloned in pX330 plasmid obtained from Feng Zhang via 
Addgene (Plasmid 42230, 3). pCBASce1 plasmid was obtained from Maria Jasin via 
Addgene (Plasmid 26477, 4). DSB reporter system plasmid (pDRR), mCherry HR donor 
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plasmid (pDonor HR mCherry), 3FLAG-C7orf49 donor plasmid (pDonor 3FLAG C7Orf49), 
mClover-LMNA donor plasmid (pDonor mClover-LMNA) and LMNA Nickase Reporter 
plasmids (pCas9D10A-sgLMNA) were obtained by DNA synthesis of gBlocks (IDT DNA) 
and cloning by InFusion (Clontech). pDRR was cloned in a pLenti CMV Neo backbone 
obtained from Eric Campeau via Addgene (Plasmid 17447, 5). pDonor HR mCherry, 
pDonor 3FLAG C7Orf49, pDonor C7Orf49 3FLAG and pDonor mClover LMNA were 
cloned in pCBA backbone (Addgene plasmid 26477). pCas9D10A-sgLMNA plasmids were 
cloned in pX460 backbone obtained from Feng Zang via Addgene (Plasmid 48873, 3). All 
plasmid maps are depicted in Extended data Figures 10-11.
Transient transfections were performed using either Nucleofection (Lonza) or 
Lipofectamine3000 (Thermo Fisher), following manufacturer’s instructions.
Lentivirus was produced by the Salk’s Gene Transfer, Targeting and Therapeutics Core 
facility or in the laboratory. For virus production, 293FT cells (Thermo Fisher) were 
transfected with 7µg of plasmid using Lenti-X Packaging Single-shot system (Clontech). 
Viral supernatant was collected 48 hours after transfection and used for cell infection at a 
multiplicity of infection (MOI) of 2 in the presence of LentiBlast (Oz biosciences). 48 hr 
after infection, cells were washed and selected with 1 µg ml-1 puromycin for two days, 800 
µg ml-1 G418 (neomycinR) for 10 days or 75 µg ml-1 Hygromycin B for 10 days. pRSITUR 
infected cells were sorted for RFP fluorescence.
List of siRNAs, sgRNAs, shRNAs and primers used
shRNAs plasmids and target sequences:
shTRF2 pLKO.1 (Open Biosystems) ACAGAAGCAGTGGTCGAATC
shLuci pRSITUR (Cellecta) CGCTGAGTACTTCGAAATGTC
shCYREN-A pRSITUR (Cellecta) CTCTGGGAATCCTGATTGAGA
shCYREN-B pRSITUR (Cellecta) GAAGAGGATGTGCTGAAATAC
shCYREN-C pRSITUR (Cellecta) GGATGTGCTGAAATACGTCGC
sgRNAs target sequences:
CYREN KO and N-ter tagging: AAGGACCCTCGTTTTAGTCT. CYREN C-ter tagging: 
GGCCGCCCGCCTGTGGGAAT. Cas9 reporter, Blunt ends: 
GGTTGGCAGCGCTGCCCGCG. 44bp 5' overhangs (Cas9D10A) or 3’ overhangs 
(Cas9N368A): GGTTGGCAGCGCTGCCCGCG & CCATGGAGACCCCGTCCCAG. 96bp 
5' overhangs: CGCTGCCAACCTGCCGGCCA & TGCTCGGAGTCGGAGTGCGC. 37bp 
3' overhangs: CCCGAGCCCCGCGCCCTTTC & ACGGGGTCTCCATGGCCGGC. 94bp 
3' overhangs: CAAGCCGAGAGCCAGCCGGC & ACGGGGTCTCCATGGCCGGC
siRNA sequences:
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Non-targeting pool (NT): UGGUUUACAUGUCGACUAA, 
UGGUUUACAUGUUGUGUGA, UGGUUUACAUGUUUUCUGA, 
UGGUUUACAUGUUUUCCUA.
CYREN 3’ UTR: CCUAGAAAGCAAACGAGCU, GCAGCUAGCUAUAAAGCAA, 
AUACACAAGUGCUAGAAAA.
ATM: GCAAAGCCCUAGUAACAUA, GGUGUGAUCUUCAGUAUAU, 
GAGAGGAGACAGCUUGUUA, GAUGGGAGGCCUAGGAUUU.
Ligase 4: GCACAAAGAUGGAGAUGUA, GGGAGUGUCUCAUGUAAUA, 
GGUAUGAGAUUCUUAGUAG, GAAGAGGGAAUUAUGGUAA.
DNA-PKcs: GGAAGAAGCUCAUUUGAUU, GAGCAUCACUUGCCUUUAA, 
GCAGGACCGUGCAAGGUUA, AGAUAGAGCUGCUAAAUGU.
Ligase 3: GGACUUGGCUGACAUGAUA, GACAUUGCCUCCAGGUGUA, 
CAGAAGUGGUGCACAGUCA, GAAGGGCGUAUGCCGAAUU.
Primers for PCR and RT-PCR:
CYREN-1: GTCCTTCCCTCATGGCTGAC & TCCTTGTCGCAGGGAGTCTT.
CYREN-2: ACTCCTGCGAATCTGACTC & AATCAGGATTCCCAGAGCA.
CYREN-3: TTGTGAGAAGACTCCCTGC & AATCAGGATTCCCAGAGCA.
ACTB: TGTACGCCAACACAGTGCTG & GCTGGAAGGTGGACAGCGA.
LMNA reporter: TACACCAGCCAACCCAGATCC & CGATCATTGAGCTCCTGCAGG
Telomere FISH and CO-FISH
For fusions analysis, cells were synchronized in metaphase with 20 ng ml-1 colcemid for 30 
min (Figure 2D) or 3 hr, collected by trypsinization and centrifuged. Hypothonic choc was 
performed 7 min at 37ºC in 75mM KCl, followed by fixation in Methanol:Acetic acid 3:1 
(v/v). After three washes in fixative solution, cells were dropped on superfrost microscope 
slides and dried over night. Slides were then rehydrated 10 min in PBS, fixed 2 min in 3.7% 
(v/v) formaldehyde in PBS and dehydrated in ethanol bath series (70%; 90%; 100%, 3 min 
each) and air dried. Slides were layered with 40µl of 0.3ng µl-1 Alexa488-OO-(CCCTAA)3 
PNA probe (PNA Bio Inc.) diluted in 70% (v/v) deionized formamide; 0.25% (v/v) blocking 
Reagent (NEN); 10mM Tris pH 7.5; 4.1mM Na2HPO4; 450µM citric acid; 1.25mM MgCl2, 
denatured 4 min at 76ºC and incubated 2 hr at room temperature. Slides were then washed 
twice 15 min 70% (v/v) formamide; 10mM TrisHCl pH 7.5 and three times 5 min in 50mM 
TrisHCl pH 7.5; 150mM NaCl; 0.08% Tween-20. Slides were stained with 50ng ml-1 DAPI, 
dehydrated in ethanol bath series, air-dried and mounted in Prolong-Gold (Thermo Fisher).
CO-FISH was performed as described 6.
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Immunoblotting
Immunoblotting was performed as described 7 and developed using a Syngene G-Box 
imager. Antibodies: TRF2 (Karlseder lab), Rabbit FLAG (Sigma-Aldrich - F7425), FLAG 
(M2, Sigma-Aldrich - F1804), Tubulin (Sigma-Aldrich – T6557), BrdU A488 (3D4, BD 
Biosciences - 555627), Ku70 (V540, Cell Signalling - 4104), Ku70 (Abcam – ab3114), 
Ku86 (Cell Signalling - 2753), ATM (Epitomics - 1549-1), Ligase 4 (EPR16531, Abcam - 
ab193353), DNA-PKcs (Abcam - ab70250), Ligase 3 (BD Biosciences - 611876), Anti-
Rabbit HRP (GE Healthcare - NXA931), Anti-Mouse HRP (GE Healthcare - NXA934V).
Peptide binding assay
Peptide binding arrays were generated as previously described 8. Membranes were activated 
by soaking 2 min in methanol, washed 5 min in TBST, blocked 5 min in TBST + 5% milk 
(TBST-M), and incubated 24 hr at 4ºC with 6 µg ml-1 of purified Ku70/Ku80 proteins in 
TBST-M, followed by incubation overnight in anti-Ku70 primary antibody diluted 1:1000 
(v/v) in TBST-M. Membranes were then washed three times 5 min in TBST, incubated 1 hr 
with secondary antibody, washed three times 15 min in TBST, revealed with ECL substrate 
and imaged with a Syngene G-Box imager.
Co-Immunoprecipitations
For Alanine scan, CYREN1-FLAG was cloned in pcDNA3.1 construct and residues 9 to 46 
were each mutated to an Alanine using Q5 Site-Directed Mutagenesis Kit (NEB). HEK293T 
cells were transfected with 10µl of empty vector, FLAG-tagged CYREN1 wt or mutants 
using Lipofectamine 2000. 24 hours post-transfection, cells were harvested and lysed with 
Pierce IP lysis buffer (Thermo Fisher) supplemented with protease inhibitors (Roche). 
Protein lysates were immunoprecipitated with anti-FLAG agarose beads (clone M2, Sigma 
Aldrich) 1 hr at 4°C for, washed 3 times with TBS-T and eluted with 125 μg ml-1 3X FLAG 
peptide (Sigma Aldrich) in TBS-T 1 hr at 4°C. 2.5% of the cell total lysate and 25% of the 
immunoprecipitate were used for western blot analysis.
For endogenous CYREN immunoprecipitations, cells were synchronized by double 
thymidine block and lysed in Pierce Lysis buffer 30 minutes after 2 Gy irradiation in S, G2 
or G1 (respectively 4, 9 and 12.5 hours after Thymidine release). 500µg of protein lysates 
were incubated overnight with 2µg of rabbit anti-Flag or control IgG antibody followed by 
one hour incubation with 50µl of Dynabeads Protein G. Beads were washed five times in 
PBST and boiled in Laemli buffer. 2.5% of the cell total lysate and 25% of the 
immunoprecipitate were used for western blot analysis.
Photo-crosslink pulldown
Purified CYREN(2-24) free peptide and cross-linkable CYREN(2-24)- (p-benzoyl-l-
phenylalanine (BPA at residue 16)-Biotin peptides were purchased from RS synthesis. 2 mg 
of HEK293T cell lysates were incubated 1 hr at 4ºC 100µM CYREN(2-24) free peptide (or 
equivalent volume of DMSO). 25-50µM CYREN(2-24)-BPA(16)-Biotin were added and 
incubation was pursued 2 hr, followed by UV crosslinking (Stratalinker 1800, 365nm) for 
one hour while maintaining samples on ice. Crosslinked samples were immunoprecipitated 1 
hr at 4ºC with 100 μL of streptavidin agarose beads (Thermo FISHER), washed 3 times with 
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TBS-T supplemented with 1% SDS at room temperature for three times, 15 min each. The 
samples were eluted with 2X SDS loading dye and boiled for 15 min at 95 °C. SDS-PAGE 
and Western blot analysis were performed.
In Vitro End-Joining Assay
Cells were wash three times in ice-cold PBS, resuspended in two volume of hypotonic lysis 
buffer (10 mM Tris-HCl, pH 8.0/ 1 mM EDTA/ 1 mM DTT plus protease inhibitors), left 20 
minutes on ice. Swollen cells were lysed by homogenization left 20 min on ice, and 0.5 
volume of high salt buffer (50 mMTris-HCl, pH 7.5/ 1MKCl/ 2mMEDTA/ 1mM DTT) was 
added. Extract was centrifuged for 1 hour at 20,000 rpm in a Beckman 70.1 Ti fixed angle 
rotor 4°C, using polycarbonate thick wall tubes. Supernatant was dialyzed for 2-3 hours 
against E buffer [20 mM Tris-HCl, pH 8.0/ 0.1 M KOAc/ 20% (vol/vol) glycerol/ 0.5 mM 
EDTA/ 1 mM DTT] in a cassette with a membrane cutoff of 10000 Da. Snap freezing in 
liquid N2 and storage at -80° C. End-Joining reactions (20 μl) were carried out in 20 mM 
Tris-HCl (pH 7.5), 01 mM Mg(OAc)2, 60 mM KOAc, 2 mM ATP, 0.5 mM DTT, and 80 
μg/ml BSA, 40 ng of cell extracts and 20 ng of 32P-labeled DNA. Incubation was for 90 
minutes at 37°C. 32P-labeledDNAproducts were deproteinized and analyzed by 
electrophoresis through 0.6% agarose gels followed by autoradiography. Quantification of 
joining efficiency was carried out using ImageJ. Linear DNA containing 3’-overhangs was 
generated by cutting the plasmid pBLueScript with the endonuclease HindIII, 5’-overhangs 
were generated cutting with KpnI and blunt ends were generating using EcoRV.
DSB Repair Reporter (DRR)
The integrated DRR consists of a promoter and resistance cassette fused to a T2A peptide 
and two inverted ISce1 sites, followed by GFP. Intact or partially cut DRR lack GFP 
expression due to the presence of a STOP codon. Cells are transfected with ISce1 and an 
exogenous donor for HR. Repair by NHEJ or HR lead to GFP or mCherry expression.
Protein alignment
We used PRALINE protein alignment online software. http://www.ibi.vu.nl/programs/
pralinewww/
Flow Cytometry
For DNA repair reporter analysis, one million cells containing integrated reporter were 
nucleofected with 4µg of pDonor HR plasmid and 2.5µg of pCBASce plasmid. 48 hr after 
transfection, cells were trypsinized and resuspended in 25mM HEPES pH 7; 1% (v/v) FBS; 
2mM EDTA; 1x PBS and directly subjected to flow cytometry analysis. For Cas9-LMNA 
reporter, 0.4 million cells were seeded in a 6-well plate and transfected 24 hours later using 
Lipofectamine 3000 with 4µg of mClover-LMNA HR donor plasmid and 2.5 µg of a plasmid 
expressing Cas9 D10A and a pair of gRNAs. Cells were analyzed by flow cytometry 72 
hours after transfection. For cell cycle analysis, cultured cells were treated 10 min with 30 
µM BrdU, fixed in PBS:Ethanol 1:3 (v/v) and labeled with Alexa488 anti BrdU and 
Propidium Iodide. Flow cytometry was performed using MACSquant Analyzer 10 
(Miltenyi) and analyzed with FlowJo10.
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Deep Sequencing
CYRENwt and KO clones were transfected as for flow cytometry analysis, except no HR 
donor was transfected. Four days after transfection, DNA was extracted using Quick-DNA 
Miniprep Plus kit (Zymo Research) and a 300nt region around the break sites was amplified 
by PCR using KOD hot start polymerase (Millipore). Transfection efficiency was controlled 
by flow cytometry with the BFP tag on the Cas9 guide RNA plasmid. PCR products were 
sequenced by MiSeq by Retrogen. The paired end fastq files were first merged into single 
continuous reads using FLASH (PMID:21903629). Reads were then aligned to the amplified 
template reference sequence of the amplified template using global Smith-Waterman 
sequence alignment with the EMBOSS Needle program using default parameters (PMID: 
10827456). Only sequences with an alignment score of at least 800 were considered 
Deletions were compiled from the alignments of correctly aligning sequences.
Statistical Analysis
Each figure legend indicates sample size and number of independent experiments. 
****P<0.0001, ***, P<0.001, **P<0.01, *P<0.05, ns non significant. To detect trends 
among multiple data sets in Fig. 1c-f, Fig. 3b-h, Fig. 4b and Extended data Fig. 2d, one-way 
ANOVA was used. Percentage of cells with fusions in Fig. 1e, Fig. 3d and Extended data 
Fig. 1e and 3f were analysed by Fisher’s exact test. Two tailed unpaired t test was used in 
Fig. 2a-b-d and Extended data Fig. 8c to compare two data sets where Gaussian distribution 
is assumed. All statistical analyses were performed using GraphPad Prism 7 software.
Source Data
All gel source data are available in Supplementary Figure 1.
Data availability statement
All data and reagents are available from the corresponding author (J.K.) upon reasonable 
request.
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Extended Data
Extended data Figure 1. CYREN depletion leads to chromatid-type fusions at deprotected 
telomeres.
a, qRT-PCR measurement of CYREN isoforms expression for Figure 1c-e. Normalized to 
ACTB qRT-PCR. CYREN-1, PCR primers target mRNA transcript variant 1. CYREN-2, 
PCR primers target mRNA transcript variants 2, 3, 4 and 5. CYREN-3, PCR primers target 
mRNA transcript variant 7. b, Western blot showing TRF2 depletion. For gel source data, 
see Supplementary Figure 1. c, Experimental outline of Figure 1c. HT1080 6TG cells stably 
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transduced with an inducible control shLuci or three different shCYREN were infected with 
shControl or shTRF2 on Day 0. shTRF2 transduced cells were selected with puromycin and 
shCYREN expression was induced with doxycyclin on Day 2. Cells were collected for 
fusion analysis on Day 5. d, Partial metaphase spreads of functional (shControl) and 
deprotected (shTRF2) telomeres after CYREN depletion. Green arrows: Chromosome-type 
fusions. Blue arrows: Chromatid-type fusions. e, Percentage of cells with fusions ± upper 
and lower value of 95% confidence intervals, Wilson/Brown test. ****P<0.0001, 
***P<0.001. Fisher’s exact test, two-sided. n: number of metaphases analysed. f, Mean 
percentage of chromosome ends fused by sister telomere associations. Error bars, s.e.m. ns. 
One-way ANOVA, Sidak’s multiple comparison test. n: number of metaphases analysed. g, 
Number of metaphases analysed, total telomere and fusions counted.
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Extended data Figure 2. Chromatid-type fusions induced by CYREN depletion in IMR90 
fibroblasts.
a, Western blot showing TRF2 depletion. For gel source data, see Supplementary Figure 1. 
b, qRT-PCR measurement of CYREN isoforms expression after siRNA knock-down. 
Normalized to ACTB qRT-PCR. CYREN-1, PCR primers target mRNA transcript variant 1. 
CYREN-2, PCR primers target mRNA transcript variants 2, 3, 4 and 5. CYREN-3, PCR 
primers target mRNA transcript variant 7. c, Representative images of partial metaphase 
spreads of functional (shControl) and deprotected (shTRF2) telomeres after CYREN 
depletion. d, Mean percentage of fused chromosome ends per metaphase. Error bars, s.e.m. 
**P<0.01. One-way ANOVA, Sidak’s multiple comparison test. n: number of metaphases 
analysed.
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Extended data Figure 3. CYREN prevents cNHEJ in S and G2 at deprotected telomeres.
a, Schematic of CO-FISH. Chromatid-type fusions involving leading and lagging strands. b, 
Percentage of fusions ± upper and lower value of 95% confidence intervals, Wilson/Brown 
test. 126 fusions counted. c, Western blot showing knockdown of ATM, Ligase 4, DNA-
PKcs and Ligase 3 in Figure 2c. For gel source data, see Supplementary Figure 1. d, 
Experimental timeline for Figure 2c. CYRENwt and CYRENKO HT1080 cells were infected 
with shTRF2 on Day 0, followed by transfection with siRNAs on Day 2. On Day 3, shTRF2 
infected cells were selected with Puromycin and cells were collected for fusion analysis on 
Day 5. e, Experimental timeline for Extended data Figure 3d. HT1080 6TG were stably 
transduced with shTRF2 on Day 0, followed by transfection with Non-Targetting (NT) or 
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CYREN siRNAs on Day 2. On Day 3, shTRF2 infected cells were selected with Puromycin 
and inhibitors were added. Cells were collected for fusion analysis on Day 5. f, Percentage 
of cells with fusions ± upper and lower value of 95% confidence intervals, Wilson/Brown 
test. Cells were treated for 48 hours with DMSO or the following inhibitors: ATMi 
(KU-55933) 10µM, DNA-PKcsi (NU-7441) 1µM, PARPi (Olaparib) 10µM, RAD51i (RI-1) 
20µM. ****P<0.0001, ns non significant. Fisher’s exact test, two-sided. Experiment shown 
is representative of two biological replicates.
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Extended data Figure 4. CYREN regulates the DSB pathway choice at intrachromosomal 
breaks.
a, Experimental timeline for Figure 3a-b. CYRENwt and CYRENKO clonal HT1080 were 
synchronised by double thymdine block, irradiated at 2 Gray 2 hours, 6 hours and 10 hours 
after Thymidine release, corresponding to S, G2 and G1 phases of the cell cycle, 
respectively. Cells were arrested for Immuno-Fluorescence or chromosome spreads 26 hours 
after thymidine release. b, Cell cycle profiles of cells used in Figure 3a-b, 2 hours, 6 hours 
and 10 hours after Thymidine release. 20,000 cells were analysed. c, Representative flow 
cytometry controls for the DSB Repair Reporter. 1 million cells per sample were analysed. 
d, Experimental outline of Fig. 3d. A single clone of HT1080 transduced with the DSB 
Repair Reporter was isolated and transfected with Cas9 and sgCYREN. Single clones were 
isolated and genotype. Selected wt and KO clones were then transfected with ISce1 and the 
HR donor, followed by flow cytometry analysis 48 hours later. e, Cell cycle distribution of 
the wt and KO clones obtained by flow cytometry of Propidium Iodide and BrdU labeled 
cells. 20,000 cells were analysed. 80,000 cells were analysed.
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Extended data Figure 5. CYREN does not regulate repair of replication-induced DSBs.
a, Representative images of chromosomes from b. b. Percentage of metaphases with radial 
chromosomes ± upper and lower value of 95% confidence intervals, Wilson/Brown test. n: 
number of metaphases analysed. Experiment shown is representative of 2 biological 
replicates. c, Percentage of survival to increasing concentrations of PARP inhibitor.
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Extended data Figure 6. CYREN isoforms 1 and 2 inhibit cNHEJ.
a, Anti-Flag western blot on whole cell extracts of HT1080 6TG expressing Flag-CYREN 
isoforms used in Fig. 4b. * indicates two non specific bands. For gel source data, see 
Supplementary Figure 1. b, Experimental outline of Fig. 4b. HT1080 6TG were stably 
transfected with pcDNA3 empty Flag vector or pcDNA3 expressing CYREN-1-Flag, 
CYREN-2-Flag or CYREN-3-Flag. Cells were selected and infected with shTRF2 on Day 0, 
followed by transfection with a control pool of Non-targeting (NT) siRNAs or a pool of 
siRNAs targeting the 3’UTR of CYREN. shTRF2 infected cells were selected on Day 3 and 
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cells were collected for fusion analysis on Day 5. c, Schematic representation of N-terminal 
3FLAG endogenous tagging of CYREN-1 and CYREN-2. d, Sequencing of the N-ter 
3FLAG-CYREN tagged allele. e, Anti-Flag western blot of whole cells extracts from 
HT1080 and HT1080 with endogenously N-terminally 3xFLAG tagged exon 1 of C7Orf49. 
Upper band, CYREN-1. Lower band, CYREN-2. Increasing amounts of protein extracts 
were loaded (5, 10, 15, 20µl). For gel source data, see Supplementary Figure 1. f, Schematic 
representation of C-terminal 3FLAG endogenous tagging of CYREN-1 and CYREN-3. g, 
Sequencing of the C-ter CYREN-3FLAG tagged allele. h, FLAG western blot of HT1080 
6TG without and with endogenously tagged C-ter CYREN-3FLAG. Increasing amounts of 
protein extracts were loaded (5, 10, 15, 20µl). For gel source data, see Supplementary Figure 
1. i, FLAG western blot of 3FLAG-CYREN tagged HT1080 following CYREN knockdown 
by siRNA. For gel source data, see Supplementary Figure 1.
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Extended data Figure 7. CYREN interaction with Ku in S and G2 inhibits cNHEJ.
a, Immunoblotting of a peptide binding array of full length CYREN-1. Each dot represents 
20 aa of CYREN-1 with 19 aa overlap with the previous and following peptide. Upper panel, 
ponceau. Middle panels, duplicate incubation with Ku70/Ku80 recombinant proteins and 
immunoblotting with anti-Ku70 antibody. Lower panel, control immunoblotting with anti-
Ku70 antibody without incubation with recombinant Ku70/80. For gel source data, see 
Supplementary Figure 1. b, Alanine scan of CYREN-1 on residues 9 to 46. FLAG 
immunoprecipitation of protein extracts from HEK293T cells transfected with pCDNA3.1 
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plasmids expressing wt CYREN-1-FLAG or each of the single residues mutated to Alanine. 
Total lysate and FLAG-IP were then immunoblotted with anti FLAG or Ku70 antibodies. 
For gel source data, see Supplementary Figure 1. c, Protein alignment of CYREN-1 Ku 
Binding Motif among vertebrates. d, Photo-crosslinked pull down of a BPA-BIO-
CYREN(2-24) peptide in HEK293T protein extract, followed by immunoblotting with anti-
Ku70 and Ku80 antibodies. + and ++, 25µM and 50µM of BPA-Bio-CYREN. 100µM of 
CYREN(2-24) free peptide was used as a competitor. For gel source data, see 
Supplementary Figure 1. e, Experimental outline of Fig. 4d. HT1080 6TG cells stably 
expressing an inducible control GFP or wt or mutant CYREN-1-3xFlag were transduced 
with shTRF2 on Day 0 and transfected with a control (NT) pool of siRNAs or a pool of 
siRNAs targeting the 3’UTR of CYREN on Day 2. Expression of CYREN-1 wt and mutants 
was induced on Day 3 and cells were collected on Day 5. f, FLAG western blot of 
endogenous C-terminal 3FLAG tagged CYREN-1 and CYREN-2 cells following double 
thymidine synchronisation. For gel source data, see Supplementary Figure 1.
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Extended data Figure 8. CYREN inhibits cNHEJ preferentially at breaks with overhangs by 
preventing processing.
a, Percentage of cells using HR to repair Cas9-induced breaks. Detail of 4 wt and 4 KO 
clones used in Fig. 5b. b, Deletion profiles of repair of Cas9-induced breaks. Detail profiles 
of 4 wt and 4 KO clones used in Fig. 5c. Blue line in blunt ends: break site. Blue area: 
overhang region created by the pair of sgRNAs. c. Average percentage of mClover+ cells in 
4 wt clones, 4 KO clones, 4 KO clones complemented with wt CYREN and 4 KO clones 
complemented with mutant CYREN (RPW-AAA), in 3 independent experiments, 
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normalized to wt. Whiskers: Tuckey. *P<0.05. Unpaired T test. In each experiment, 100,000 
cells per sample were analysed. d, Deletion profiles of repair of Cas9 breaks. Average 
percentage of deletion in wt, KO clones, and KO clones complemented with wt CYREN or 
mutant CYREN (RPW-AAA). Error bars, s.e.m.
Extended data Figure 9. CYREN does not promote cNHEJ in vitro.
a, In vitro cNHEJ assay using CYRENwt and CYRENKO cells. Left panel: Immunoblots of 
extracts used in the assay. Middle panel: In Vitro ligation assay. Right panel: quantification. 
Error bars: standard deviation, 3 independent experiments. For gel source data, see 
Supplementary Figure 1. b, In vitro cNHEJ assay using CYRENwt cells and increasing 
amounts of recombinant wt CYREN and CYRENΔKu mutant. Right panel: quantification. 
For gel source data, see Supplementary Figure 1.
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Extended data Figure 10. Maps of plasmids used in Figures 1-2-3-4-5.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. CYREN depletion reactivates cNHEJ in S and G2 at deprotected telomeres.
a, Schematic outcome of telomere fusions. b, Partial metaphase spreads of deprotected 
(shTRF2) telomeres after CYREN depletion. Green arrows: Chromosome-type fusions. Blue 
arrows: Chromatid-type fusions. c, Mean percentage of fused chromosome ends per 
metaphase, separated in chromosome-type and chromatid-type fusions. Error bars, s.e.m. 
**P<0.01, *P<0.05. One-way ANOVA, Sidak’s multiple comparison test. n: number of 
metaphases analysed. Experiment shown is representative of two biological replicates. d, 
Cell cycle profiles of cells from c. 12,000 cells were analysed. e, Percentage of cells with 
fusions ± upper and lower value of 95% confidence intervals, Wilson/Brown test. 
****P<0.0001, ***P<0.001, **P<0.01. Fisher’s exact test, two-sided. n: number of 
metaphases analysed. f, Upper panel, experimental outline. Lower panel, mean percentage of 
fused ends per metaphase. Error bars, s.e.m. ***P<0.001, **P<0.01, *P<0.05. One-way 
ANOVA. Sidak’s multiple comparison test. n: number of metaphases analysed. Experiment 
shown is representative of two biological replicates.
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Figure 2. CYREN inhibits NHEJ at intrachromosomal breaks.
a, Average number of rearranged chromosomes per cell ± upper and lower value of 95% 
confidence intervals, Wilson/Brown test. ****P<0.0001. Two-tailed unpaired t-test. 120 
metaphases analysed per condition in 3 biological replicates. b, Percentage of cells with a 
bridge ± upper and lower value of 95% confidence intervals, Wilson/Brown test. 
***P<0.001. Two-tailed unpaired t-test. 300 cells analysed in 3 biological replicates. c, d, 
Percentage of GFP+ and mCherry+ cells, gated on BFP+, of five biological replicates. Mean 
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± s.d. is indicated. Gray line, mean of all wt or KO clones. P values, unpaired T test between 
wt and KO clones. In each experiment, 1 million cells per sample were analysed.
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Figure 3. CYREN interaction with Ku in S and G2 inhibits cNHEJ.
a, CYREN isoforms. b, Mean percentage of fused ends per metaphase. Error bars, s.e.m. 
***P<0.001, *P<0.05, ns non significant. One-way ANOVA, Sidak’s multiple comparison 
test. n: number of metaphases analysed. Experiment shown is representative of two 
biological replicates. c, Co-Immunoprecipitation of CYREN-1-3FLAG with Ku70/80 in 
HEK293T. For gel source data see Supplementary Figure 1. d, Percentage of fusions ± upper 
and lower value of 95% confidence intervals, Wilson/Brown test. ***P<0.001, **P<0.01, ns 
non significant. Fisher’s exact test, two-sided. e, Relative abundance of CYREN-1 and 2 
mRNA in double Thymidine synchronized cells. f, Immunoblotting of 3FLAG-CYREN-1 in 
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double Thymidine synchronized cells. g. FLAG immunoprecipitation of CYREN1-3FLAG 
with 2 Gy irradiation followed by FLAG and Ku70 immunoblotting in double Thymidine 
synchronized cells. *unspecific band. For gel source data see Supplementary Figure 1. 
Experiment shown is representative of 4 biological replicates. h, Quantification of g. Error 
bars, s.e.m. over 4 independent experiments. **P<0.01. Ordinary one-way ANOVA.
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Figure 4. CYREN prevents overhang processing.
a, LMNA Cas9 reporter. CRISPR/Cas9 and sgRNAs target the 5’ UTR of LMNA. HR fuses 
mClover to LMNA for repair. Cas9 with sgRNAs (red arrows) generate different breaks. b, 
Average percentage of mClover+ cells in 4 wt and 4 KO clones in 5 independent 
experiments, normalized to wt. Whiskers: Tuckey. ***P<0.001, *P<0.05. Ordinary one-way 
ANOVA. In each experiment, 250,000 cells per sample were analysed. c, Deletion profiles 
of repair of Cas9 breaks. Average percentage of deletion in 4 wt and 4 KO clones. Error 
bars, s.e.m. Blue line in blunt ends: break site. Blue area: overhang region created by the pair 
of sgRNAs.
Arnoult et al. Page 32
Nature. Author manuscript; available in PMC 2018 March 20.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
